Health technology assessment : HTA
-
Health Technol Assess · Aug 2013
ReviewEchocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation.
To investigate the clinical effectiveness and cost-effectiveness of transthoracic echocardiography (TTE) in all patients who are newly diagnosed with atrial fibrillation (AF). ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Aug 2013
ReviewHome telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation.
Remote monitoring (RM) strategies have the potential to deliver specialised care and management to patients with heart failure (HF). ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Jul 2013
ReviewClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
The National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. ⋯ The National Institute for Health Research Health Technology Assessment.
-
Health Technol Assess · Jul 2013
ReviewSystematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Jul 2013
ReviewCombined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway. ⋯ The National Institute for Health Research Health Technology Assessment programme.